Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 4/20 | 0.44 |
| ▸ | NPY1R | P25929 | 3/20 | 0.44 |
| ▸ | NPY2R | P49146 | 3/20 | 0.44 |
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30484834 | 0.97 | NPY4R (0.47) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL30484831 | 0.96 | NPY4R (0.46) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL29473686 | 0.92 | NMT2 (0.47) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL30484828 | 0.92 | MME (0.47) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL29886546 | 0.91 | NMT1 (0.47) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL30484829 | 0.91 | NPY1R (0.42) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL29666896 | 0.90 | NPY4R (0.50) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL30478747 | 0.89 | NMT2 (0.49) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL29354569 | 0.89 | MME (0.48) | NPY4RNPY1RNPY2RNMT2NMT1 | |
| SCHEMBL30439682 | 0.87 | MME (0.49) | NPY4RNPY1RNPY2RNMT2NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | disclosed |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2024-08-29 | — | — | US | disclosed |
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIP, LNPEP, CSTB | NPY4R 862/4885NPY1R 832/4885NPY2R 1244/4885 |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIP, QPCT, QPCTL | NPY4R 171/4885NPY1R 246/4885NPY2R 654/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | NPY4R 742/4885NPY1R 678/4885NPY2R 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.